Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials

Malfertheiner, 2022, Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report, Gut, 71, 1724, 10.1136/gutjnl-2022-327745 Liou, 2020, Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus, Gut, 69, 2093, 10.1136/gutjnl-2020-322368 Katelaris, 2023, Helicobacter pylori World Gastroenterology Organization Global Guideline, J Clin Gastroenterol, 57, 111, 10.1097/MCG.0000000000001719 Graham, 2022, Cross-roads for meta-analysis and network meta-analysis of H pylori therapy, Gut, 71, 643, 10.1136/gutjnl-2021-326170 Ma, 2022, Tailored therapy for Helicobacter pylori eradication: a systematic review and meta-analysis, Front Pharmacol, 13 Nyssen, 2022, Empirical vs susceptibility-guided treatment of Helicobacter pylori infection: a systematic review and meta-analysis, Front Microbiol, 13, 10.3389/fmicb.2022.913436 Liou, 2018, Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection, Gastroenterology, 155, 1109, 10.1053/j.gastro.2018.06.047 Liou, 2013, Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial, J Antimicrob Chemother, 68, 450, 10.1093/jac/dks407 Mégraud, 2007, Helicobacter pylori detection and antimicrobial susceptibility testing, Clin Microbiol Rev, 20, 280, 10.1128/CMR.00033-06 Gisbert, 2008, “Rescue” regimens after Helicobacter pylori treatment failure, World J Gastroenterol, 14, 5385, 10.3748/wjg.14.5385 Graham, 2022, Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: when, how, why, Am J Gastroenterol, 117, 524, 10.14309/ajg.0000000000001659 Liou, 2011, Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies, Antimicrob Agents Chemother, 55, 1123, 10.1128/AAC.01131-10 Mégraud, 2004, H pylori antibiotic resistance: prevalence, importance, and advances in testing, Gut, 53, 1374, 10.1136/gut.2003.022111 Liou, 2013, Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial, Lancet, 381, 205, 10.1016/S0140-6736(12)61579-7 Tshibangu-Kabamba, 2021, Helicobacter pylori infection and antibiotic resistance—from biology to clinical implications, Nat Rev Gastroenterol Hepatol, 18, 613, 10.1038/s41575-021-00449-x Chen, 2017, Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials, J Antimicrob Chemother, 72, 3481, 10.1093/jac/dkx320 Wang, 2018, A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori, Helicobacter, 23, 10.1111/hel.12467 Lange, 2020, Perspective for precision medicine for tuberculosis, Front Immunol, 11, 10.3389/fimmu.2020.566608 Walker, 2022, The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis, Lancet Microbe, 3, e265, 10.1016/S2666-5247(21)00301-3 Liou, 2018, 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial, J Antimicrob Chemother, 73, 2510, 10.1093/jac/dky183 Liou, 2023, Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial, Lancet Gastroenterol Hepatol, 8, 228, 10.1016/S2468-1253(22)00384-3 Graham, 2016, Hp-normogram (normo-graham) for assessing the outcome of H pylori therapy: effect of resistance, duration, and CYP2C19 genotype, Helicobacter, 21, 85, 10.1111/hel.12287 Mégraud, 2015, Molecular approaches to identify Helicobacter pylori antimicrobial resistance, Gastroenterol Clin North Am, 44, 577, 10.1016/j.gtc.2015.05.002 Ierardi, 2017, Noninvasive molecular analysis of Helicobacter pylori: is it time for tailored first-line therapy?, World J Gastroenterol, 23, 2453, 10.3748/wjg.v23.i14.2453 De Francesco, 2006, Clarithromycin-resistant genotypes and eradication of Helicobacter pylori, Ann Intern Med, 144, 94, 10.7326/0003-4819-144-2-200601170-00006 Lee, 2013, Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance, J Infect Dis, 208, 1123, 10.1093/infdis/jit287 Seo, 2019, Helicobacter pylori eradication according to sequencing-based 23S ribosomal RNA point mutation associated with clarithromycin resistance, J Clin Med, 9, 54, 10.3390/jcm9010054 Ong, 2019, Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: a multicenter randomized controlled trial, Helicobacter, 24, 10.1111/hel.12654 Nezami, 2019, Helicobacter pylori mutations detected by next-generation sequencing in formalin-fixed, paraffin-embedded gastric biopsy specimens are associated with treatment failure, J Clin Microbiol, 57, e01834, 10.1128/JCM.01834-18 Kouhsari, 2022, Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis, Ann Clin Microbiol Antimicrob, 21, 19, 10.1186/s12941-022-00509-3 Kocsmár, 2020, Helicobacter pylori heteroresistance to clarithromycin in adults—new data by in situ detection and improved concept, Helicobacter, 25, 10.1111/hel.12670 Kocsmár, 2021, Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides, Nat Commun, 12, 10.1038/s41467-021-22557-7 Keikha, 2022, Prevalence of antibiotic heteroresistance associated with Helicobacter pylori infection: a systematic review and meta-analysis, Microb Pathog, 170, 10.1016/j.micpath.2022.105720